Literature DB >> 6841997

Studies on histamine metabolism in mastocytosis.

G Granerus, J H Olafsson, G Roupe.   

Abstract

The urinary excretion of histamine and its main metabolite, 1-methyl-4-imidazoleacetic acid (MeImAA), was determined in 30 adult patients with the clinical diagnosis of urticaria pigmentosa (UP). Clinical and laboratory investigations including skin histology, bone marrow examination, and scintigraphy of the skeleton, liver, and spleen revealed systemic manifestations in 14 cases. Among the 16 cases with dermal proliferation of mast cells only 3 cases classified as telangiectasia macularis eruptiva perstans (TMEP). All patients with systemic mastocytosis and UP excreted increased amounts of MeImAA in the urine while normal amounts were found in 2 of the patients with TMEP. A significant correlation existed between MeImAA excretion and the extent of mast cell infiltration in skin and internal organs. No such correlation was found for urinary histamine. Urinary MeImAA but not histamine is therefore considered a useful indicator of systemic involvement by reflecting the size of the mast cell histamine pool. The main symptom of the patients was pruritus, which was moderate to severe in 17 and mild or absent in 13 cases. Gastrointestinal symptoms were present in 14 patients. However, there was no obvious correlation between the excretion of MeImAA and any of the symptoms recorded. Neither was the severity of pruritus correlated to the histamine content of the skin, which was measured in both lesional and unaffected skin in 23 of the patients. Thus, symptoms possibly caused by histamine in mastocytosis patients are not directly related to urinary histamine metabolite excretion or tissue histamine content.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6841997     DOI: 10.1111/1523-1747.ep12555351

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  No relationship between histamine release measured as metabolite excretion in the urine, and serum levels of mast cell specific tryptase in mastocytosis.

Authors:  G Granerus; B Lönnqvist; G Roupe
Journal:  Agents Actions       Date:  1994-06

2.  Histamine metabolism in mastocytosis patients treated with interferon alpha-2b.

Authors:  G Granerus; B Lönnqvist; G Roupe
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

3.  Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study.

Authors:  J H Olafsson; O Larkö; G Roupe; G Granerus; U Bengtsson
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

4.  Serum levels of neutrophil and eosinophil chemotactic activities in mastocytosis.

Authors:  G Granerus; L Håkansson; G Roupe; P Venge
Journal:  Agents Actions       Date:  1989-04

5.  Treatment of two mastocytosis patients with a histidine decarboxylase inhibitor.

Authors:  G Granerus; J H Olafsson; G Roupe
Journal:  Agents Actions       Date:  1985-04

6.  Alpha-fluoromethylhistidine in the treatment of idiopathic cold urticaria.

Authors:  H Neittaanmäki; J E Fräki; R J Harvima; L Förström
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

Review 7.  The role of mast cells in common gastrointestinal diseases.

Authors:  Ali A Siddiqui; Philip B Miner
Journal:  Curr Allergy Asthma Rep       Date:  2004-01       Impact factor: 4.919

8.  Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis.

Authors:  Do-Kyun Kim; Michael A Beaven; Joseph M Kulinski; Avanti Desai; Geethani Bandara; Yun Bai; Calman Prussin; Lawrence B Schwartz; Hirsh Komarow; Dean D Metcalfe; Ana Olivera
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.